Zoetis Inc (NYSE:ZTS) Receives $113.62 Consensus PT from Analysts

Shares of Zoetis Inc (NYSE:ZTS) have earned an average rating of “Buy” from the fifteen ratings firms that are currently covering the firm, Marketbeat reports. Seven equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $113.62.

Several research analysts have recently commented on the stock. Zacks Investment Research lowered shares of GALP ENERGIA SG/ADR from a “hold” rating to a “sell” rating in a report on Monday, May 6th. BMO Capital Markets lifted their price objective on shares of goeasy from C$55.00 to C$60.00 in a research report on Thursday, May 9th. Credit Suisse Group cut their price objective on shares of Diplomat Pharmacy from $10.00 to $8.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 2nd. Barclays reiterated a “hold” rating on shares of Bank of Montreal in a research report on Tuesday, June 11th. Finally, Bank of America set a $221.00 price target on shares of Constellation Brands and gave the stock a “buy” rating in a research report on Monday, July 1st.

In related news, insider Roxanne Lagano sold 29,453 shares of the firm’s stock in a transaction on Friday, May 10th. The shares were sold at an average price of $101.65, for a total value of $2,993,897.45. Following the completion of the transaction, the insider now directly owns 58,180 shares of the company’s stock, valued at $5,913,997. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Clinton A. Jr. Lewis sold 6,123 shares of the firm’s stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $101.90, for a total transaction of $623,933.70. Following the completion of the transaction, the executive vice president now directly owns 51,926 shares of the company’s stock, valued at $5,291,259.40. The disclosure for this sale can be found here. Insiders sold a total of 76,613 shares of company stock worth $7,963,366 over the last quarter. 0.29% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently made changes to their positions in ZTS. Dimensional Fund Advisors LP raised its stake in Zoetis by 2.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,425,455 shares of the company’s stock valued at $121,929,000 after purchasing an additional 39,319 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Zoetis by 14.4% during the fourth quarter. Geode Capital Management LLC now owns 6,227,976 shares of the company’s stock worth $531,801,000 after purchasing an additional 785,088 shares during the last quarter. Cetera Advisors LLC lifted its stake in shares of Zoetis by 7.9% in the fourth quarter. Cetera Advisors LLC now owns 9,097 shares of the company’s stock worth $787,000 after acquiring an additional 667 shares during the period. Cetera Investment Advisers lifted its stake in Zoetis by 9.3% in the fourth quarter. Cetera Investment Advisers now owns 4,289 shares of the company’s stock valued at $368,000 after buying an additional 365 shares during the period. Finally, Advisory Services Network LLC lifted its stake in Zoetis by 8.3% in the fourth quarter. Advisory Services Network LLC now owns 4,490 shares of the company’s stock valued at $383,000 after buying an additional 344 shares during the period. 90.11% of the stock is owned by institutional investors and hedge funds.

Shares of NYSE ZTS traded down $0.16 during midday trading on Thursday, hitting $115.39. The company’s stock had a trading volume of 74,150 shares, compared to its average volume of 1,534,476. Zoetis has a 1-year low of $78.90 and a 1-year high of $116.69. The business has a fifty day simple moving average of $113.52. The company has a debt-to-equity ratio of 2.84, a quick ratio of 2.79 and a current ratio of 4.05. The firm has a market cap of $55.31 billion, a price-to-earnings ratio of 36.87, a P/E/G ratio of 3.14 and a beta of 0.91.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, May 2nd. The company reported $0.88 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.79 by $0.09. Zoetis had a net margin of 23.47% and a return on equity of 73.66%. The business had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.45 billion. During the same period in the previous year, the business posted $0.75 EPS. The company’s quarterly revenue was up 6.5% on a year-over-year basis. On average, equities research analysts forecast that Zoetis will post 3.48 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 19th will be given a dividend of $0.164 per share. The ex-dividend date of this dividend is Thursday, July 18th. This represents a $0.66 dividend on an annualized basis and a yield of 0.57%. Zoetis’s payout ratio is presently 21.09%.

Zoetis Company Profile

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Read More: What is the Current Ratio?

Analyst Recommendations for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.